Clinical data | |
---|---|
Trade names | Anatropin, Neo-Novum |
Other names | ORF-1658; Anapregnone acetate; 3-Deketo-6α-methyl-17α-acetoxyprogesterone; 6α-Methyl-17α-hydroxypregn-4-en-20-one acetate |
Routes of administration | By mouth |
Drug class | Progestogen; Progestin; Progestogen ester |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.019.578 |
Chemical and physical data | |
Formula | C24H36O3 |
Molar mass | 372.549 g·mol−1 |
3D model (JSmol) | |
| |
|
Anagestone acetate, sold under the brand names Anatropin and Neo-Novum, is a progestin medication which was withdrawn from medical use due to carcinogenicity observed in animal studies.[1][2][3]